Back

Selected ressource details

-
Back

Psychedelic Psychiatry’s Brave New World


Web link: linkinghub.elsevier.com/retrieve/...

Pages: 24 - 28

Abstract

After a legally mandated, decades-long global arrest of research on psychedelic drugs, investigation of psychedelics in the context of psychiatric disorders is yielding exciting results. Outcomes of neuroscience and clinical research into 5-Hydroxytryptamine 2A (5-HT2A) receptor agonists, such as psilocybin, show promise for addressing a range of serious disorders, including depression and addiction.